SCHEMBL16010979

SCHEMBL16010979

NC(=O)C(CCCCC(=O)Nc1cncc(Br)c1)c1ccccc1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 15/20 0.66
MEF2D Q14814 6/20 0.43
HDAC1 Q13547 9/20 0.40
HDAC3 O15379 8/20 0.40
HDAC2 Q92769 8/20 0.40
HDAC10 Q969S8 7/20 0.40
HDAC6 Q9UBN7 7/20 0.40
HDAC7 Q8WUI4 6/20 0.40
HDAC11 Q96DB2 6/20 0.40
HDAC8 Q9BY41 6/20 0.40
HDAC9 Q9UKV0 6/20 0.40
HDAC5 Q9UQL6 6/20 0.40
NCOR2 Q9Y618 3/20 0.40
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1063952 0.82 HDAC1 (0.58) HDAC4HDAC1HDAC3HDAC2HDAC10
SCHEMBL1060811 0.81 HDAC1 (0.60) HDAC4HDAC1HDAC3HDAC2HDAC10
SCHEMBL16010937 0.80 HDAC4 (0.45) HDAC4MEF2DHDAC1HDAC3HDAC2
SCHEMBL16011052 0.79 HDAC4 (0.60) HDAC4HDAC1HDAC3HDAC2HDAC10
SCHEMBL16010981 0.79 HDAC4 (1.00) HDAC4HDAC1HDAC3HDAC2HDAC10
SCHEMBL16011100 0.79 HDAC4 (0.63) HDAC4MEF2DHDAC1HDAC3HDAC2
SCHEMBL1065607 0.78 HDAC1 (0.61) HDAC4HDAC1HDAC3HDAC2HDAC10
SCHEMBL16010906 0.78 HDAC3 (0.52) HDAC4HDAC1HDAC3HDAC2HDAC10
SCHEMBL1064516 0.75 HDAC4 (0.62) HDAC4MEF2DHDAC1HDAC3HDAC2
SCHEMBL1063215 0.74 HDAC3 (0.55) HDAC4MEF2DHDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2994122-A1 NOVEL TRANSCRIPTION FACTOR MODULATORS C & C Biopharma, LLC (US) 2016-03-16 EP disclosed
US-9133105-B2 Transcription factor modulators C&C BIOPHARMA, LLC (US) 2015-09-15 US disclosed
WO-2014138508-A1 NOVEL TRANSCRIPTION FACTOR MODULATORS C & C BIOPHARMA, LLC (US) 2014-09-12 WO disclosed
US-20140256775-A1 NOVEL TRANSCRIPTION FACTOR MODULATORS C & C BIOPHARMA LLC (US) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256775-A1 NOVEL TRANSCRIPTION FACTOR MODULATORS RELA, CBFB, CREBBP HDAC4 224/4885MEF2D 255/4885HDAC1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.